Stockreport
Cytokinetics Announces Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal Muscular Atrophy to be Presented at the 2018 Annual Cure SMA Conference on June 16, 2018
Last cytokinetics, inc earnings: 11/1 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations: ir.cytokinetics.com/investor-overview
PDF
SOUTH SAN FRANCISCO, Calif., June 08, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that data from the Phase 2 clinical study of reldesemtiv in patients with spinal muscular atrophy (SMA) will be presented in an oral presentation at the 2018 Annual Cure SMA Conference in Dallas on June 16, 2018. Date: Saturday, June 16, 2018Location: Hilton Anatole Hotel, Imperial BallroomSession: Preclinical and Clinical Drug DevelopmentPresentation Time: 10:40-11:00 AM CDTTitle: Update of CY 5021: A Phase 2 Clinical Trial of Reldesemtiv, a Fast Skeletal Muscle Troponin Activator (FSTA), for the Potential Treatment of Spinal Muscular AtrophySpeaker: John Day, M.D., Ph.D., Professor of Neurology and Pediatrics (Genetics), Stanford University Medical Center About Cytokinetics Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating disea
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | CYTK | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
CYTK alerts
CYTK alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYTK alerts
High impacting Cytokinetics, Inc news events
Weekly update
A roundup of the hottest topics
CYTK
NEWS
NEWS
- Cytokinetics to Announce Fourth Quarter Results on February 21, 2019[GlobeNewswire]
- Cytokinetics up 4% premarket on FDA signoff on endpoint for pivotal study of reldesmetiv in SMA [Seeking Alpha][Seeking Alpha]
- Cytokinetics Announces Receipt of FDA Feedback Regarding Reldesemtiv in Patients With SMA[GlobeNewswire]
- Cytokinetics, Inc. (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.[MarketBeat]
- Cytokinetics, Inc. (NASDAQ: CYTK) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $7.75 price target on the stock.[MarketBeat]
- More
CYTK
SEC Filings
SEC Filings
- 2/14/19 - Form SC
- 2/14/19 - Form SC
- 2/12/19 - Form SC
- CYTK's page on the SEC website
- More